buyWeak cluster of 5
Harold Eugene Brakewood bought $4,804 of IMRX
Chief Business Officer at Immuneering Corp. 1,900 shares at an average of $2.53, traded Jun 20, 2025, filed Jun 24, 2025.
Conviction score
36Value
$4,804
1,900 shares
Holdings after
5,800
+49% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$5k at market
- +6Relative to holdingsHoldings up 49%
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001790340-25-000085, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 20, 2025 | POpen-market purchase Class A Common Stock | +1,900 | $2.53 | $4,804 | 5,800 | Jun 24, 2025 |
Related signals
Other insiders at Immuneering Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 47Moderate | Immuneering Corp | Thomas J. Schall director | $35k 9,500 shares | +22% | |
| 36Weak | Immuneering Corp | Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | $35k 13,422 shares | +4% | |
| 44Moderate | Immuneering Corp | Peter Feinberg director | $63k 25,000 shares | +22% | |
| 42Moderate | Immuneering Corp | Benjamin J. Zeskind PRESIDENT AND CEO | $50k 21,000 shares | +1% | |
| 49Moderate | Immuneering Corp | Thomas J. Schall director | $89k 40,485 shares | +1396% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.